{"transactions":[{"id":867957,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-03T16:18:01.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":14204,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":14204,"derivative":{"exercise_price":13.78,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":14204},"source":{"system":"sec-edgar","filing":"0001193125-26-088258","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000119312526088258/ownership.xml","form_type":"4"}},{"id":867956,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-03T16:18:01.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":9943,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":131192,"source":{"system":"sec-edgar","filing":"0001193125-26-088258","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000119312526088258/ownership.xml","form_type":"4"}},{"id":944597,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-07T16:04:38.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":11903,"price":9.21,"value":109626.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,022 and 1,264 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively."}],"balance_after":121249,"source":{"system":"sec-edgar","filing":"0001193125-26-006283","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000119312526006283/ownership.xml","form_type":"4"}},{"id":1229178,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-04T16:26:23.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":61714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2025 with respect to shares of Common Stock, with 33% vesting on January 1, 2026 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":61714,"derivative":{"exercise_price":10.09,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":61714},"source":{"system":"sec-edgar","filing":"0000950170-25-032125","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000095017025032125/ownership.xml","form_type":"4"}},{"id":1229177,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-04T16:26:23.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":43200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":130866,"source":{"system":"sec-edgar","filing":"0000950170-25-032125","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000095017025032125/ownership.xml","form_type":"4"}},{"id":1308214,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-07T17:20:25.000Z","date":"2025-01-03","kind":"sale","planned":false,"acquired":false,"shares":9557,"price":12.18,"value":116404.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":87666,"source":{"system":"sec-edgar","filing":"0000950170-25-003015","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000095017025003015/ownership.xml","form_type":"4"}},{"id":1315071,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-01-03T16:30:06.000Z","date":"2025-01-01","kind":"exercise","planned":false,"acquired":false,"shares":3189,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 3, 2021, the reporting person was granted 12,750 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."}],"balance_after":0,"derivative":{"exercise_date":"2025-01-01","expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":3189},"source":{"system":"sec-edgar","filing":"0000950170-25-001237","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000095017025001237/ownership.xml","form_type":"4"}},{"id":1315070,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-03T16:30:06.000Z","date":"2025-01-01","kind":"exercise","planned":false,"acquired":true,"shares":3189,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 405 and 556 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2024 and December 31, 2024, respectively."}],"balance_after":97223,"source":{"system":"sec-edgar","filing":"0000950170-25-001237","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000095017025001237/ownership.xml","form_type":"4"}},{"id":1597035,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-05T16:10:10.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":55855,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2024 with respect to shares of Common Stock, with 33% vesting on January 1, 2025 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":55855,"derivative":{"exercise_price":32.66,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":55855},"source":{"system":"sec-edgar","filing":"0000950170-24-025904","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000095017024025904/ownership.xml","form_type":"4"}},{"id":1597034,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-03-05T16:10:10.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":38701,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":93073,"source":{"system":"sec-edgar","filing":"0000950170-24-025904","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000095017024025904/ownership.xml","form_type":"4"}},{"id":1685609,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-05T16:50:36.000Z","date":"2024-01-03","kind":"sale","planned":false,"acquired":false,"shares":5843,"price":29.46,"value":172134.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2024, and does not represent a volitional trade by the Reporting Person."}],"balance_after":54372,"source":{"system":"sec-edgar","filing":"0000950170-24-002515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000095017024002515/ownership.xml","form_type":"4"}},{"id":1692949,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-01-03T17:34:10.000Z","date":"2024-01-01","kind":"exercise","planned":false,"acquired":false,"shares":3187,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 3, 2021, the reporting person was granted 12,750 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."}],"balance_after":3189,"derivative":{"exercise_date":"2024-01-01","expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":3187},"source":{"system":"sec-edgar","filing":"0000950170-24-001204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000095017024001204/ownership.xml","form_type":"4"}},{"id":1692948,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-03T17:34:10.000Z","date":"2024-01-01","kind":"exercise","planned":false,"acquired":true,"shares":3187,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 360 and 307 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2023 and December 31, 2023, respectively."}],"balance_after":60215,"source":{"system":"sec-edgar","filing":"0000950170-24-001204","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000095017024001204/ownership.xml","form_type":"4"}},{"id":1974330,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-03T17:15:53.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":43342,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2023 with respect to shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":43342,"derivative":{"exercise_price":40.75,"expiration_date":"2033-02-28","underlying":"Common Stock","underlying_shares":43342},"source":{"system":"sec-edgar","filing":"0001209191-23-015753","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919123015753/doc4.xml","form_type":"4"}},{"id":1974329,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-03T17:15:53.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":30674,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":56361,"source":{"system":"sec-edgar","filing":"0001209191-23-015753","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919123015753/doc4.xml","form_type":"4"}},{"id":2060560,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-06T17:26:38.000Z","date":"2023-01-04","kind":"sale","acquired":false,"shares":2574,"price":37.21,"value":95778.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023."}],"balance_after":25687,"source":{"system":"sec-edgar","filing":"0001209191-23-002417","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919123002417/doc4.xml","form_type":"4"}},{"id":2068333,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2023-01-04T20:33:03.000Z","date":"2023-01-01","kind":"exercise","acquired":false,"shares":3187,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 3, 2021, the reporting person was granted 12,750 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 3, 2021, the reporting person was granted 12,750 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."}],"balance_after":6376,"derivative":{"exercise_date":"2023-01-01","expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":3187},"source":{"system":"sec-edgar","filing":"0001209191-23-001492","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919123001492/doc4.xml","form_type":"4"}},{"id":2068332,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-04T20:33:03.000Z","date":"2023-01-01","kind":"exercise","acquired":true,"shares":3187,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 105 and 231 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2022 and December 31, 2022, respectively."}],"balance_after":28261,"source":{"system":"sec-edgar","filing":"0001209191-23-001492","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919123001492/doc4.xml","form_type":"4"}},{"id":2350595,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-04T21:01:05.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":20203,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 incorrectly reported the number of options granted as 13,816."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The original Form 4 incorrectly reported the number of options granted as 13,816."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The original Form 4 incorrectly reported the number of options granted as 13,816."}],"balance_after":20203,"derivative":{"exercise_price":79.85,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":20203},"source":{"system":"sec-edgar","filing":"0001209191-22-016533","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919122016533/doc4a.xml","form_type":"4/A","original_submission_date":"2022-03-03"}},{"id":2355129,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-03T20:00:07.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":13816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":13816,"derivative":{"exercise_price":79.85,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":13816},"source":{"system":"sec-edgar","filing":"0001209191-22-015960","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919122015960/doc4.xml","form_type":"4"}},{"id":2355128,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2022-03-03T20:00:07.000Z","date":"2022-01-01","kind":"exercise","acquired":false,"shares":3187,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 3, 2021, the reporting person was granted 12,750 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 3, 2021, the reporting person was granted 12,750 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter."}],"balance_after":9563,"derivative":{"exercise_date":"2022-01-01","expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":3187},"source":{"system":"sec-edgar","filing":"0001209191-22-015960","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919122015960/doc4.xml","form_type":"4"}},{"id":2355127,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-03T20:00:07.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":13816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":24738,"source":{"system":"sec-edgar","filing":"0001209191-22-015960","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919122015960/doc4.xml","form_type":"4"}},{"id":2355126,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-03T20:00:07.000Z","date":"2022-01-01","kind":"sale","acquired":false,"shares":1051,"price":112.24,"value":117964.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2022."}],"balance_after":10922,"source":{"system":"sec-edgar","filing":"0001209191-22-015960","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919122015960/doc4.xml","form_type":"4"}},{"id":2355125,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-03T20:00:07.000Z","date":"2022-01-01","kind":"exercise","acquired":true,"shares":3187,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 72 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2021."}],"balance_after":11973,"source":{"system":"sec-edgar","filing":"0001209191-22-015960","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919122015960/doc4.xml","form_type":"4"}},{"id":2519859,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-09T18:08:44.000Z","date":"2021-11-05","kind":"exercise","acquired":false,"shares":2400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 75,000 shares as of November 5, 2021."}],"balance_after":180077,"derivative":{"exercise_price":12.62,"expiration_date":"2030-04-30","underlying":"Common Stock","underlying_shares":2400},"source":{"system":"sec-edgar","filing":"0001209191-21-063698","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121063698/doc4.xml","form_type":"4"}},{"id":2519858,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-11-09T18:08:44.000Z","date":"2021-11-05","kind":"sale","acquired":false,"shares":200,"price":135.34,"value":27068.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":8714,"source":{"system":"sec-edgar","filing":"0001209191-21-063698","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121063698/doc4.xml","form_type":"4"}},{"id":2519857,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-11-09T18:08:44.000Z","date":"2021-11-05","kind":"sale","acquired":false,"shares":548,"price":134.07,"value":73470.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.79 to $134.67, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 5, 2021 at each separate price."}],"balance_after":8914,"source":{"system":"sec-edgar","filing":"0001209191-21-063698","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121063698/doc4.xml","form_type":"4"}},{"id":2519856,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-11-09T18:08:44.000Z","date":"2021-11-05","kind":"sale","acquired":false,"shares":452,"price":132.62,"value":59944.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.42 to $133.32, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 5, 2021 at each separate price."}],"balance_after":9462,"source":{"system":"sec-edgar","filing":"0001209191-21-063698","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121063698/doc4.xml","form_type":"4"}},{"id":2519855,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-11-09T18:08:44.000Z","date":"2021-11-05","kind":"sale","acquired":false,"shares":1200,"price":131.71,"value":158052.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.36 to $132.055, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 5, 2021 at each separate price."}],"balance_after":9914,"source":{"system":"sec-edgar","filing":"0001209191-21-063698","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121063698/doc4.xml","form_type":"4"}},{"id":2519854,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-11-09T18:08:44.000Z","date":"2021-11-05","kind":"exercise","acquired":true,"shares":2400,"price":12.62,"value":30288.0,"ownership":{"direct":true},"balance_after":11114,"source":{"system":"sec-edgar","filing":"0001209191-21-063698","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121063698/doc4.xml","form_type":"4"}},{"id":2541750,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-10-15T19:02:26.000Z","date":"2021-10-14","kind":"exercise","acquired":false,"shares":2400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 70,833 shares as of October 14, 2021."}],"balance_after":182477,"derivative":{"exercise_price":12.62,"expiration_date":"2030-04-30","underlying":"Common Stock","underlying_shares":2400},"source":{"system":"sec-edgar","filing":"0001209191-21-060638","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121060638/doc4.xml","form_type":"4"}},{"id":2541749,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-15T19:02:26.000Z","date":"2021-10-14","kind":"sale","acquired":false,"shares":250,"price":130.47,"value":32617.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.425 to $130.66, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2021 at each separate price."}],"balance_after":8714,"source":{"system":"sec-edgar","filing":"0001209191-21-060638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121060638/doc4.xml","form_type":"4"}},{"id":2541748,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-15T19:02:26.000Z","date":"2021-10-14","kind":"sale","acquired":false,"shares":525,"price":129.83,"value":68160.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.41 to $130.09, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2021 at each separate price."}],"balance_after":8964,"source":{"system":"sec-edgar","filing":"0001209191-21-060638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121060638/doc4.xml","form_type":"4"}},{"id":2541747,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-15T19:02:26.000Z","date":"2021-10-14","kind":"sale","acquired":false,"shares":225,"price":129.01,"value":29027.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.40 to $129.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2021 at each separate price."}],"balance_after":9489,"source":{"system":"sec-edgar","filing":"0001209191-21-060638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121060638/doc4.xml","form_type":"4"}},{"id":2541746,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-15T19:02:26.000Z","date":"2021-10-14","kind":"sale","acquired":false,"shares":849,"price":127.81,"value":108510.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.38 to $128.26, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2021 at each separate price."}],"balance_after":9714,"source":{"system":"sec-edgar","filing":"0001209191-21-060638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121060638/doc4.xml","form_type":"4"}},{"id":2541745,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-15T19:02:26.000Z","date":"2021-10-14","kind":"sale","acquired":false,"shares":551,"price":126.92,"value":69932.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.345 to $127.32, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2021 at each separate price."}],"balance_after":10563,"source":{"system":"sec-edgar","filing":"0001209191-21-060638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121060638/doc4.xml","form_type":"4"}},{"id":2541744,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-15T19:02:26.000Z","date":"2021-10-14","kind":"exercise","acquired":true,"shares":2400,"price":12.62,"value":30288.0,"ownership":{"direct":true},"balance_after":11114,"source":{"system":"sec-edgar","filing":"0001209191-21-060638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121060638/doc4.xml","form_type":"4"}},{"id":2558948,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-27T16:15:17.000Z","date":"2021-09-24","kind":"exercise","acquired":false,"shares":7923,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 66,666 shares as of September 24, 2021."}],"balance_after":184877,"derivative":{"exercise_price":12.62,"expiration_date":"2030-04-30","underlying":"Common Stock","underlying_shares":7923},"source":{"system":"sec-edgar","filing":"0001209191-21-057778","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121057778/doc4.xml","form_type":"4"}},{"id":2558947,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-27T16:15:17.000Z","date":"2021-09-24","kind":"exercise","acquired":true,"shares":7923,"price":12.62,"value":99988.26,"ownership":{"direct":true},"balance_after":8714,"source":{"system":"sec-edgar","filing":"0001209191-21-057778","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121057778/doc4.xml","form_type":"4"}},{"id":2561030,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-23T17:48:09.000Z","date":"2021-09-21","kind":"exercise","acquired":false,"shares":2400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 66,666 shares as of September 21, 2021."}],"balance_after":192800,"derivative":{"exercise_price":12.62,"expiration_date":"2030-04-30","underlying":"Common Stock","underlying_shares":2400},"source":{"system":"sec-edgar","filing":"0001209191-21-057475","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121057475/doc4.xml","form_type":"4"}},{"id":2561029,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-23T17:48:09.000Z","date":"2021-09-21","kind":"sale","acquired":false,"shares":2400,"price":149.81,"value":359544.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":791,"source":{"system":"sec-edgar","filing":"0001209191-21-057475","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121057475/doc4.xml","form_type":"4"}},{"id":2561028,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-23T17:48:09.000Z","date":"2021-09-21","kind":"exercise","acquired":true,"shares":2400,"price":12.62,"value":30288.0,"ownership":{"direct":true},"balance_after":3191,"source":{"system":"sec-edgar","filing":"0001209191-21-057475","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121057475/doc4.xml","form_type":"4"}},{"id":2583777,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-01T19:32:58.000Z","date":"2021-08-30","kind":"exercise","acquired":false,"shares":2400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 62,500 shares as of August 30, 2021."}],"balance_after":195200,"derivative":{"exercise_price":12.62,"expiration_date":"2030-05-04","underlying":"Common Stock","underlying_shares":2400},"source":{"system":"sec-edgar","filing":"0001209191-21-054317","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121054317/doc4.xml","form_type":"4"}},{"id":2583776,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-01T19:32:58.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":150,"price":160.1,"value":24015.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.02 to $160.97, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":791,"source":{"system":"sec-edgar","filing":"0001209191-21-054317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121054317/doc4.xml","form_type":"4"}},{"id":2583775,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-01T19:32:58.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":1100,"price":159.19,"value":175109.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.55 to $159.50, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":941,"source":{"system":"sec-edgar","filing":"0001209191-21-054317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121054317/doc4.xml","form_type":"4"}},{"id":2583774,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-01T19:32:58.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":250,"price":157.6,"value":39400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.29 to $157.89, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":2041,"source":{"system":"sec-edgar","filing":"0001209191-21-054317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121054317/doc4.xml","form_type":"4"}},{"id":2583773,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-01T19:32:58.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":700,"price":156.7,"value":109690.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.29 to $157.13, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":2291,"source":{"system":"sec-edgar","filing":"0001209191-21-054317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121054317/doc4.xml","form_type":"4"}},{"id":2583772,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-01T19:32:58.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":200,"price":155.43,"value":31086.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.10 to $155.76, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 30, 2021 at each separate price."}],"balance_after":2991,"source":{"system":"sec-edgar","filing":"0001209191-21-054317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121054317/doc4.xml","form_type":"4"}},{"id":2583771,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-01T19:32:58.000Z","date":"2021-08-30","kind":"exercise","acquired":true,"shares":2400,"price":12.62,"value":30288.0,"ownership":{"direct":true},"balance_after":3191,"source":{"system":"sec-edgar","filing":"0001209191-21-054317","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121054317/doc4.xml","form_type":"4"}},{"id":2607014,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-08-11T16:50:08.000Z","date":"2021-08-09","kind":"exercise","acquired":false,"shares":2400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 62,500 shares as of August 9, 2021."}],"balance_after":197600,"derivative":{"exercise_price":12.62,"expiration_date":"2030-05-04","underlying":"Common Stock","underlying_shares":2400},"source":{"system":"sec-edgar","filing":"0001209191-21-050881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121050881/doc4.xml","form_type":"4"}},{"id":2607013,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-08-11T16:50:08.000Z","date":"2021-08-09","kind":"sale","acquired":false,"shares":2400,"price":164.05,"value":393720.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 568 and 223 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2020 and June 30, 2021, respectively."}],"balance_after":791,"source":{"system":"sec-edgar","filing":"0001209191-21-050881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121050881/doc4.xml","form_type":"4"}},{"id":2607012,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-08-11T16:50:08.000Z","date":"2021-08-09","kind":"exercise","acquired":true,"shares":2400,"price":12.62,"value":30288.0,"ownership":{"direct":true},"balance_after":3191,"source":{"system":"sec-edgar","filing":"0001209191-21-050881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121050881/doc4.xml","form_type":"4"}},{"id":2806546,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2021-03-05T17:49:55.000Z","date":"2021-03-03","kind":"grant","acquired":true,"shares":12750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On March 3, 2021, the reporting person was granted 12,750 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."},{"field":"date","element":"transactionDate","label":"F2","text":"On March 3, 2021, the reporting person was granted 12,750 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 3, 2021, the reporting person was granted 12,750 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 3, 2021, the reporting person was granted 12,750 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."}],"balance_after":12750,"derivative":{"underlying":"Common Stock","underlying_shares":12750},"source":{"system":"sec-edgar","filing":"0001209191-21-018322","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121018322/doc4.xml","form_type":"4"}},{"id":2806545,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-05T17:49:55.000Z","date":"2021-03-03","kind":"grant","acquired":true,"shares":76500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on March 3, 2021 with respect to 76,500 shares of Common Stock, with 25% vesting on January 1, 2022 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":76500,"derivative":{"exercise_price":57.71,"expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":76500},"source":{"system":"sec-edgar","filing":"0001209191-21-018322","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919121018322/doc4.xml","form_type":"4"}},{"id":3161508,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63353,"kind":"person","name":"Lebwohl David","position":1,"cik":"0001810882","reported_name":"Lebwohl David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-05T16:49:00.000Z","date":"2020-05-01","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 1, 2020 with respect to 200,000 shares of Common Stock, with 25% vesting on May 1, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":200000,"derivative":{"exercise_price":12.62,"expiration_date":"2030-04-30","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-20-027165","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810882/000120919120027165/doc4.xml","form_type":"4"}}]}